ABO-incompatible living donor liver transplantation: New insights into clinical relevance

Transplantation

Volumn 85, Issue 11, 2008, Pages 1523-1525

  Kawagishi, Naoki ^a   Satomi, Susumu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ABO incompatible; Apheresis; Infusion therapy; Living donor liver transplantation; Rituximab

Indexed keywords

GABEXATE MESILATE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PROSTAGLANDIN E1; RITUXIMAB;

ANEURYSM; APHERESIS; B CELL LYMPHOMA; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL PROTOCOL; DRUG MEGADOSE; GRAFT SURVIVAL; HEPATIC ARTERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE; KIDNEY GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM CARE; LYMPHOMA; ORGAN DONOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SHORT SURVEY; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOSIS; TRANSPLANTATION TOLERANCE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; LIVING DONOR; METHODOLOGY; PREOPERATIVE CARE; PROGNOSIS; REVIEW;

ABO BLOOD-GROUP SYSTEM; BLOOD COMPONENT REMOVAL; BLOOD GROUP INCOMPATIBILITY; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; LIVING DONORS; PREOPERATIVE CARE; PROGNOSIS;

EID: 47049084271     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318173a70e     Document Type: Short Survey

References (13)

1. Toso C, Al-Qahtani M, Alsaif FA, et al. ABO-incompatible liver transplantation for critically ill adult patients. Transpl Int 2007; 20: 675.
2. Tullius SG. Promising recent data on ABO incompatible liver transplantation: Restrictions may apply. Transpl Int 2007; 20: 647.
3. Egawa H, Oike F, Buhler L, et al. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 2004; 77: 403.
4. KozakiK,EgawaH, KasaharaM,et al. Therapeutic strategy and the role of apheresis therapy for ABO incompatible living donor liver transplantation. Ther Apher Dial 2005; 9: 285.
5. Kawagishi N, Takeda I, Miyagi S, et al. Management of anti-allogeneic antibody elimination by apheresis inliving donor liver transplantation. Ther Apher Dial 2007; 11: 319.
6. Mor E, Skerrett D, Manzarbeita C, et al. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. Transplantation 1995; 59: 986.
7. TanabeM,ShimazuM,WakabayashiG,etal. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 2002; 73: 1959.
8. The Japanese Liver Transplantation Society. Liver transplantation in Japan-registry by the Japanese Liver Transplantation Society (in Japanese with English abstract). Isyoku 2005; 40: 518.
9. Takahashi K. Recent findings in ABO-incompatible kidney transplan- tation: Classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishmentofaccommodation.Clin Exp Nephrol 2007; 11: 128.
10. Usuda M, Fujimori K, Koyamada N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005; 79: 12.
11. Monteiro I, McLoughlin L, Fisher A, et al. Rituximab with plasma- pheresis and splenectomy in ABO-incompatible liver transplantation. Transplantation 2003; 76: 1648.
12. Egawa H, Ohmori K, Haga H, et al. B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 2007; 13: 579.
13. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: Efficacy, safety, and cost implications. Am J Transplat 2003; 3: 653.